NCT01157052Unknown1 期
Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- The primary objective of this study is to determine potential pharmacokinetic interactions between oxaliplatin and calcium and magnesium.
研究概览
简要总结
The investigators hypothesize that Ca2+/MG2+ infusions will not have a significant effect on oxaliplatin pharmacokinetics.
详细描述
This is a clinical pharmacology prospective non-randomized trial to determine oxaliplatin pharmacokinetics in the presence and absence of calcium and magnesium supplementation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have Metastatic Colorectal Cancer (stage IV)
- •Patients who were treated with 5FU and leucovorin in the adjuvant setting or with 5FU and leucovorin (LV)or/and FOLFIRI regimen for metastatic setting may be eligible for this trial.
- •Patients must be ≥ 18 years
- •Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •Patients must have adequate renal function of creatinine < 1.5mg/dl and a creatinine clearance > 45ml/min. Patients must have adequate hepatic function with a bilirubin > 1.5 mg/dl and AST (normal range 0-14/L) and ALT (normal range 0-49 U/L) in the absence of liver metastasis or </= 5X the upper limit of normal of AST and ALT in the presence of liver metastasis.
- •Patients must have adequate bone marrow function with absolute neutrophil count(ANC)≥ 1,500/цl and platelets ≥ 100,000/цl and a hemoglobin ≥ 10g/d.
- •Patients must be willing and able to comply with the study protocol for the study duration and patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.
- •Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment. Also,women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. The investigator is requested to advise the patient how to achieve an adequate contraception.
- •Life expectancy longer that 6 months
排除标准
- •Patients who have received oxaliplatin previously
- •Patients with known peripheral neuropathy ≥ grade 2 according to the WHO scale
- •Patients who have tested positive for HIV
- •Patients with other significant medical, psychiatric disorders tha, in the opinion of the investigator, will exclude the patient from the study for compliance of safety reasons.
- •Patients who cannot swallow
- •History of known allergy to oxaliplatin or other platinum compounds,to 5-FU, to LV, or to any ingredients in the formulations or the containers
- •Participation in another clinical trial with any investigational drug within 30 days prior to study screening
- •Pernicious anemia or other megaloblastic anemia with vitamin B12 deficiency
- •Patient with concomitant treatment with drugs/ingredients reported to have a potential activity to prevent peripheral sensory neuropathy (PSN)
- •Patients who haven't successfully completed local therapy for previously treated CNS metastases & who haven't been discontinued with corticosteroid for >4kws before starting chemotherapy. Patients with asymptomatic brain mets who have no evidence of midline shift on CT/MRI may be enrolled without initiation of local therapy for the CNS mets. Repeat scan must be performed < 4wks to ensure no progression.
结局指标
主要结局
The primary objective of this study is to determine potential pharmacokinetic interactions between oxaliplatin and calcium and magnesium.
时间窗: Post cycle 2 and 3
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
A randomized phase II study of oxaliplatin and capecitabine combination vs irinotecan and capecitabine combination for the treatment of elderly patients with advanced colorectal cancer.EUCTR2004-001159-12-ITAZIENDA OSPEDALIERA S. CARLO
已完成
2 期
Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal CarcinomaGastroesophageal CancerEsophageal CancerNCT00525915M.D. Anderson Cancer Center126
已完成
1 期
Phase I/II study of the combination of Oxaliplatin and S-1 in patients with advanced/recurrent colorectal cancerunresectable advanced/recurrent colorectal cancerJPRN-C000000443Outpatient Oncology Unit Kyoto University Hospital42
已完成
2 期
A phase II study of oxaliplatin, folinic acid and 5-fluorouracil (modified FOLFOX-6) combination chemotherapy as adjuvant treatment after resection of liver metastases from colorectal cancerliver metastases of colorectal cancerJPRN-UMIN000000996Miyagi HBPCOG50
招募中
2 期
The Effectiveness of mirogabalin on peripheral neuropathy among patients treated with oxaliplatiPeripheralneuropathicpainChemotherapy-induced peripheral neuropathyD010523JPRN-jRCT1041210094Watanabe Daichi60